Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: A crucial role for the CYP2B6*6 allele-Science-Chemical Encyclopedia-lookchem

Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of Sibutramine (cas 106650-56-0) therapy: A crucial role for the CYP2B6*6 allele
Add time:08/09/2019 Source:sciencedirect.com

BackgroundVarious cytochrome P450 isoforms modulate Sibutramine (cas 106650-56-0) activity and influence sibutramine plasma levels and pharmacokinetics. However, there are no available data to demonstrate the association of these polymorphisms with the clinical outcomes of sibutramine administration.

We also recommend Trading Suppliers and Manufacturers of Sibutramine (cas 106650-56-0). Pls Click Website Link as below: cas 106650-56-0 suppliers

Prev:Characterization, stability, and pharmacokinetics of Sibutramine (cas 106650-56-0)/β-cyclodextrin inclusion complex
Next: Molecular structure of 2-chloromethyl-1H-benzimidazole hydrochloride: Single crystal, spectral, biological studies, and DFT calculations)

Click to view details

Encyclopedia